U.S. Physical Therapy, Inc. (USPH) P/E Ratio History
Historical price-to-earnings valuation from 1996 to 2026
Loading P/E history...
USPH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, U.S. Physical Therapy, Inc. (USPH) trades at a price-to-earnings ratio of 51.8x, with a stock price of $73.61 and trailing twelve-month earnings per share of $0.70.
The current P/E is roughly in line with its 5-year average of 52.8x. Over the past five years, USPH's P/E has ranged from a low of 23.4x to a high of 149.9x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, USPH trades at a 134% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, USPH commands a significant premium over the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our USPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
USPH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 22.1 | 0.96 | +17% | |
| $10B | 30.1 | 2.18 | +14% | |
| $2B | 13.9Lowest | - | -29% | |
| $3B | 16.1 | - | +3% | |
| $2B | 18.5 | 0.92Best | +23%Best | |
| $7B | 52.7 | - | -4% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
USPH Historical P/E Data (1996–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $74.96 | $0.50 | 149.9x | +335% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $78.09 | $1.42 | 55.0x | +60% |
| FY2025 Q3 | $84.95 | $2.38 | 35.7x | +4% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $78.20 | $2.29 | 34.1x | -1% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $72.36 | $2.18 | 33.2x | -4% |
| FY2024 Q4 | $88.71 | $1.84 | 48.2x | +40% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $84.63 | $0.94 | 90.0x | +161% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $92.42 | $1.06 | 87.2x | +153% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $112.87 | $1.23 | 91.8x | +166% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $93.14 | $1.65 | 56.4x | +64% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $91.73 | $2.23 | 41.1x | +19% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $121.39 | $2.44 | 49.8x | +44% |
Average P/E for displayed period: 34.4x
See USPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs USPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare USPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonUSPH — Frequently Asked Questions
Quick answers to the most common questions about buying USPH stock.
Is USPH stock overvalued or undervalued?
USPH trades at 51.8x P/E, near its 5-year average of 52.8x. The 70th percentile ranking places valuation within normal historical bounds.
How does USPH's valuation compare to peers?
U.S. Physical Therapy, Inc. P/E of 51.8x compares to sector median of 22.1x. The premium reflects expected growth above peers.
What is USPH's PEG ratio?
USPH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1996-2026.